BFRI NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Biofrontera Inc · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 1.17 USD
7.3% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 23.0% above the Trend Line and sits at 86.0% of its 52-week range. The latest completed week returned 7.3%, after a 15.8% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 53/100. Near-term considerations: earnings are due in 8d.

Setup score 68 out of 100
Latest Close 1.17 USD 31 Jul 2026
1W Return 7.3% latest completed week
4W Return 15.8% short-term follow-through
12W Return 1.7% quarterly tape
Trend Breadth 48.1% 25 of 52 weeks active
Volume Ratio 2.1x vs 13-week average
What is working
  • The trend backdrop is active with a 7-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
  • Volume is elevated versus the 13-week average, confirming attention.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 40.39% based on similar historical setup states.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 7.3% Latest completed week; four-week move 15.8%. Indicator stack 51/100 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 40.39% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 53/100 48 relevant articles in the latest sentiment read. Event risk 8d Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 23.0% above the Trend Line and sits at 86.0% of its 52-week range. The latest completed week returned 7.3%, after a 15.8% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 2.1x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.4612-week average 0.50

12-week confirmation

Trend active11/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure7/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership4/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.46Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 15.8% over four weeks, 1.7% over 12 weeks, and 12.5% over one year. The current trend has remained active for 7 consecutive weeks.

Performance by holding period

1W7.3%
4W15.8%
12W1.7%
26W25.8%
52W12.5%
Active trend streak7 weeks
Active weeks in one year25
Trend breadth48.1%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.44Latest activity-pressure read.
Pressure change813.3%Four-week change in activity pressure.
Leadership15.34Latest relative-leadership reading.
RS change439.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 02 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength71/100Blend of value, momentum, and quality. Underlying universe rank 30; rank 1 is best.
Value60/100Relative valuation strength. Underlying universe rank 41; rank 1 is best.
Quality58/100Profitability and accounting quality. Underlying universe rank 43; rank 1 is best.
Momentum61/100Medium-term price momentum. Underlying universe rank 40; rank 1 is best.
Growth60/100Revenue and earnings growth. Underlying universe rank 41; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
0.3x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-56.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
82.8%
Gross profit retained from each unit of revenue.
Operating margin
-25.1%
Operating profit retained from revenue.
Free-cash-flow margin
-21.5%
Free cash flow generated from revenue.
Return on invested capital
-108.7%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
13.7%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-72.4%
Net share repurchases relative to market value.
Shareholder yield
-72.4%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment53/100

Weighted news tone is neutral across 48 relevant articles.

12 positive · 34 neutral · 2 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings8dNext report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-7.9%Distance below the 52-week high.
13-week volatility10.7%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher15 of 269 weeks finished lower.
Best week+19.6%Week of 3 Apr.
Worst week-30.4%Week of 15 May.
Latest week+7.3%Week of 31 Jul.

Shape of recent returns

Strong gains11
Modest gains4
Flat weeks2
Modest losses3
Sharp losses6
Recent vol10.7%13-week weekly-return volatility.
Base vol9.4%52-week weekly-return volatility.
Up/down split26/22Count of positive and negative weeks in the 52-week window.
Average skew7.6% / -7.4%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape65/100

Trend, activity pressure, participation, and risk combine to a 65/100 tape read.

 Indicator analysis58/100

Latest 12-week confirmation: trend 11/12, activity pressure 7/12, relative leadership 4/12.

Activity pressure 0.46; No reversal markers Next-Week ExpectancyNegative 40.39%

Next-week expectancy is negative with a 40.39% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors62/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 98 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment53/100

Weighted news tone is neutral across 48 relevant articles.

Form 4 Biofrontera Inc For: 29 July By Investing.com Insiders50/100

No recent insider transaction evidence is stored.

 Earnings8d

Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20261.17 USD7.3%0.95 USD1.69 USD0.4415.343.2MOn
24 Jul 20261.09 USD0.0%0.94 USD1.76 USD0.267.79754.2KOn
17 Jul 20261.09 USD-0.9%0.92 USD1.83 USD0.275.681.4MOn
10 Jul 20261.10 USD8.9%0.91 USD1.90 USD0.232.202.9MOn
3 Jul 20261.01 USD4.0%0.90 USD1.95 USD-0.06-4.521.5MOn
26 Jun 20260.97 USD-1.6%0.90 USD2.00 USD-0.16-7.231.6MOn
19 Jun 20260.99 USD14.1%0.89 USD2.06 USD-0.31-9.621.4MOn
12 Jun 20260.87 USD-7.5%0.88 USD2.12 USD-0.43-18.49595.8KOff
5 Jun 20260.94 USD5.5%0.88 USD2.17 USD-0.32-9.941.0MOn
29 May 20260.89 USD9.7%0.89 USD2.22 USD0.04-18.30332.6KOn
22 May 20260.81 USD0.9%0.89 USD2.28 USD0.40-23.29873.4KOn
15 May 20260.80 USD-30.4%0.90 USD2.33 USD0.79-23.193.1MOn
8 May 20261.15 USD6.5%0.91 USD2.39 USD1.119.88823.6KOn
1 May 20261.08 USD0.0%0.90 USD2.44 USD1.039.13617.1KOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.